The round was led by Venrock with participation from RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Greg Bailey and Litmore Capital as well as two undisclosed blue chip pharmaceutical companies (as part of in-licensing agreements with Biohaven).
The company intends to use the funds to advance its late stage clinical programs in orphan neurologic indications and other trials. Biohaven plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
Led by Vlad Coric, M.D., CEO, and Declan Doogan, M.D., Chairman, Biohaven has a portfolio of multiple late stage drug assets. The company, which has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC, Massachusetts General Hospital and two undisclosed pharmaceutical companies, has advanced multiple candidates into the clinic and plans on pivotal trials beginning late 2016.
Biohaven also has a substantial equity stake in Kleo Pharmaceuticals, Inc..
FinSMEs
01/11/2016